Ovarian Cancer Trial, Recruiting (NCT03296826)

Ovarian Cancer Trial, Recruiting NCT03296826 Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan Condition: Ovarian Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT03296826 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ovarian Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women who carry a change (variant) in the BRCA1 or BRCA2 gene, including those with changes in both genes, or those with a gene change whose meaning is not yet fully understood (called a "variant of uncertain significance")
Women who have already received genetic counseling at any medical facility before joining the study
Women who are 20 years of age or older
Women who are willing and able to give written consent to take part

Who may not be able to join:

Women who have been diagnosed with ovarian cancer or fallopian tube cancer at the time they are asked to join the study (confirm with trial site)
Women who have previously been diagnosed with ovarian cancer, fallopian tube cancer, or peritoneal (abdominal lining) cancer — note that having a personal history of breast cancer does not automatically exclude someone (confirm with trial site)
Women who the study doctor considers unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Akira Hirasawa, M.D., Ph.D., Okayama University

Phone: +81-86-235-7436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03296826

Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Phase: Not Applicable

Status: Recruiting

Condition: Ovarian Cancer

Trial contact: +81-86-235-7436

More information: https://clinicaltrials.gov/study/NCT03296826

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women who carry a change (variant) in the BRCA1 or BRCA2 gene, including those with changes in both genes, or those with a gene change whose meaning is not yet fully understood (called a "variant of uncertain significance")
Women who have already received genetic counseling at any medical facility before joining the study
Women who are 20 years of age or older
Women who are willing and able to give written consent to take part

Who may not be able to join:

Women who have been diagnosed with ovarian cancer or fallopian tube cancer at the time they are asked to join the study (confirm with trial site)
Women who have previously been diagnosed with ovarian cancer, fallopian tube cancer, or peritoneal (abdominal lining) cancer — note that having a personal history of breast cancer does not automatically exclude someone (confirm with trial site)
Women who the study doctor considers unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Registry

ClinicalTrials.gov

Start date

8 November 2017

Est. completion

31 March 2032

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Occurrence of ovarian, fallopian tube, and peritoneal carcinoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov